AIV Logo AIV Assistant

Loading...

Earnings Recaps

Browse reported earnings of the most popular stocks

40 companies Today
Absci Corporation Common Stock logo
AB
Absci Corporation Common Stock
ABSI
Q2 2025
Reported:

Absci's Q2 2025 results reflect significant advancements in its clinical pipeline, including the initiation of Phase I trials for ABS-101 and promising preclinical data for ABS-201, bolstered by a strengthened balance sheet through recent funding.

Key takeaways
  • Initiated Phase I clinical trials for ABS-101, a key anti-TL1A antibody, with interim results expected later this year.
  • Progressing towards a Phase I/IIa trial for ABS-201, targeting androgenetic alopecia, anticipated to start in early 2026.
  • Successfully raised approximately $64 million in gross proceeds to enhance the balance sheet and support ongoing projects.
  • Ongoing discussions with multiple partners for potential drug creation collaborations, including a large pharmaceutical company.
  • Continued development of innovative antibody programs and AI-driven drug creation platform, demonstrating strong interest from prospective partners.
More info
Allurion Technologies Inc. logo
AL
Allurion Technologies Inc.
ALUR
Q2 2025
Reported:

Allurion Technologies reported a transformative second quarter, highlighting strategic pivots towards innovative obesity care solutions and a strong performance in key growth accounts.

Key takeaways
  • Transitioned distribution strategy to focus on partners promoting comprehensive obesity management, resulting in a 20% growth in targeted accounts.
  • Initiated development of a novel GLP-1 drug-eluting intragastric balloon, addressing adherence issues and enhancing treatment efficacy.
  • Submitted the final module of the PMA application on schedule, demonstrating significant weight loss efficacy exceeding preset target margins.
  • Resized sales force to prioritize high-performing accounts, positioning for long-term growth potential outside the U.S. market.
  • Launched a multicenter study in Europe to validate combination therapy's impact on weight loss and GLP-1 adherence, with enrollment expected by year-end.
More info
Brenntag SE logo
BN
Brenntag SE
BNR.DE
Q2 2025
Reported:

Brenntag SE reported a challenging second quarter in 2025, with sales declining 4% year-over-year to EUR 3.9 billion, attributed to geopolitical tensions and demand slowdown. Operating EBITA saw a significant decrease of 14%, leading to adjusted guidance for the full year amidst ongoing pressures.

Key takeaways
  • Operating gross profit fell by 2% to EUR 974 million, with gross profit as a percentage of sales at 25.2%.
  • Free cash flow generated was EUR 153 million, supporting underlying cost management amid rising operational expenses.
  • The company adjusted its full-year operating EBITA forecast to EUR 950 million to EUR 1.050 billion, reflecting ongoing economic uncertainties.
  • Successful acquisitions, including MCE Pharma, position Brenntag to enhance its biopharma market presence and service offerings.
  • Recognition for sustainability efforts was highlighted, with a Gold rating from EcoVadis and an A- rating in the latest CDP climate assessment, underscoring commitment to environmental goals.
More info
CAVA Group, Inc. logo
CA
CAVA Group, Inc.
CAVA
Q2 2025
Reported:

CAVA's Q2 2025 performance reflects strong momentum with a 20.3% revenue increase year-over-year and strategic expansion, positioning the brand as a leader in the expanding Mediterranean cuisine market.

Key takeaways
  • Revenue reached $137.8 million, marking a 20.3% increase from Q2 2024 and a 62.6% rise over two years.
  • Adjusted EBITDA rose 22.6% to $42.1 million, showcasing operational efficiency and profitability.
  • The company opened 16 new restaurants, bringing the total to 398, signaling strong demand and a robust growth trajectory.
  • Same-restaurant sales grew 2.1%, reflecting ongoing brand strength despite challenging comparisons from previous year's launches.
  • Market tests for new menu items like chicken shawarma show positive early results, indicating potential for future growth and innovation.
More info
Commonwealth Bank of Australia logo
CB
Commonwealth Bank of Australia
CBA.AX
Q4 2025
Reported:

Commonwealth Bank of Australia reported a strong financial year, achieving record risk-weighted asset growth of $29 billion alongside a sustainable dividend of $4.85, underscoring its commitment to long-term investment and operational strength.

Key takeaways
  • Increased lending of $42 billion to businesses, supporting local economic growth.
  • Significant investments of over $900 million in fraud prevention, resulting in a 76% reduction in customer losses from scams.
  • Paid $8 billion in dividends, benefiting over 13 million Australians.
  • Strengthened balance sheet positions the bank to effectively support customers amidst economic uncertainty.
  • A refreshed strategy focusing on building the future economy and enhancing customer experiences through technology and AI initiatives.
More info
CIM Commercial Trust Corporation logo
CM
CIM Commercial Trust Corporation
CMCT
Q2 2025
Reported:

Creative Media & Community Trust Corporation reported mixed results for Q2 2025, with a notable increase in leasing activity but ongoing challenges in net operating income.

Key takeaways
  • Executed approximately 140,000 square feet of leases year-to-date, a 55% increase from the prior year, largely driven by properties in Los Angeles and Austin.
  • Core Funds From Operations (FFO) reported at negative $7.2 million, with overall net operating income decreasing to $9.8 million from $11.8 million in the previous quarter.
  • Positive trends in multifamily portfolio with a $800,000 increase in NOI, attributed to lower costs and improved performance at consolidated properties.
  • Continued focus on improving balance sheet and liquidity, successfully extending debt maturities and securing financing on multiple assets.
  • Anticipate further NOI growth in 2026 supported by rising office leasing activity, completed hotel renovations, and improved occupancy rates in multifamily properties.
More info
Creative Realities, Inc. logo
CR
Creative Realities, Inc.
CREX
Q2 2025
Reported:

Creative Realities delivered a solid Q2 2025 performance with a 34% quarter-over-quarter revenue increase to $13 million, though year-over-year revenue remained flat amidst margin compression.

Key takeaways
  • Adjusted EBITDA rose to $1.2 million, up from $0.5 million in Q1 2025, signaling improved operational efficiency despite a decline from $1.5 million year-over-year.
  • Annual recurring revenue (ARR) grew to $18.1 million, reflecting a strategic shift towards increasing SaaS demand and customer deployments.
  • The company successfully reduced debt by $3.1 million during the quarter, allowing for a more strategic approach to cash flow management and deleveraging.
  • A significant new client engagement with a major restaurant chain could catalyze future revenue growth and enhance partnership opportunities in digital engagement solutions.
  • Continued investment in the AdLogic CPM+ platform has resulted in increased customer interest and could drive revenue growth through in-store retail media networks.
More info
Dream Unlimited Corp. logo
DR
Dream Unlimited Corp.
DRM.TO
Q2 2025
Reported:

Dream Unlimited Corp. continues to advance its development projects significantly in Western Canada, particularly with the approval of 1,200 acres of land in Regina, setting the stage for sustained income growth.

Key takeaways
  • Secured approval for 1,200 acres in Regina, expected to generate consistent income over the next 20 years.
  • Successful commercial land sales in Saskatoon signal strong demand and faster development timelines.
  • Income properties nearing 1,000 units, with a projected 6% cap rate and positive absorption trends in Western Canada.
  • Asset management has grown by $2.5 billion year-over-year, contributing to overall business momentum.
  • Ontario income properties face rental rate softening, but the Distillery District remains a strong performer.
More info
E.ON SE logo
EO
E.ON SE
EOAN.DE
Q2 2025
Reported:

E.ON reported robust H1 2025 results, achieving an adjusted EBITDA of EUR 5.5 billion and adjusted net income of EUR 1.9 billion, while confirming it remains on track to meet full-year guidance.

Key takeaways
  • CapEx-backed growth increased by 11% year-over-year, underpinned by ongoing transformation in energy networks and reliable demand across European markets.
  • Significant advancements in digitization, including the creation of a digital twin for E.ON’s extensive power grid, enhancing resource allocation and grid stability.
  • Established strategic partnerships, such as with CyrusOne, to support innovative local energy solutions for data centers, reinforcing E.ON's role in energy infrastructure.
  • Despite operational successes, regulatory proposals for Germany's upcoming power framework are perceived as insufficient to attract necessary capital for future investments.
More info
Evotec SE American Depositary Shares logo
EV
Evotec SE American Depositary Shares
EVO
Q2 2025
Reported:

Evotec SE reported a 5% decline in first-half 2025 revenues to EUR 371 million, reflecting challenges in the Discovery & Preclinical Development segment, while Just - Evotec Biologics continued to thrive with 16% revenue growth.

Key takeaways
  • Discovery & Preclinical Development revenues fell by 11%, impacted by temporary changes in the BMS collaboration and a soft drug discovery market.
  • Just - Evotec Biologics outperformed expectations, demonstrating strong demand and achieving 16% year-over-year revenue growth.
  • A planned sale of the Toulouse site to Sandoz aligns with Evotec's strategy to enhance its capabilities in biologics manufacturing with a scalable, asset-light model.
  • A strategic reorganization is underway to simplify the business structure and enhance operational accountability.
  • Market conditions remain challenging, particularly for early-stage biotech funding, but signs of recovery are emerging.
More info
Evotec SE logo
EV
Evotec SE
EVT.DE
Q2 2025
Reported:

Evotec SE reported a 5% decline in total revenues for H1 2025, driven primarily by an 11% drop in the Discovery & Preclinical Development segment, while Just - Evotec Biologics demonstrated strong growth with 16% revenue increase, highlighting the effectiveness of the company's strategic transformation.

Key takeaways
  • Total group revenues for H1 2025 reached EUR 371 million, down from H1 2024, with temporary disruptions impacting BMS collaboration.
  • Just - Evotec Biologics (JEB) achieved significant growth, solidifying its position as a leader in biologics manufacturing.
  • Initiatives to streamline operations and align organizational structure with strategic goals are underway, aimed at enhancing accountability and performance.
  • Market conditions remain challenging, particularly in early-stage biotech funding, although signs of recovery are beginning to emerge.
  • The planned sale of the Toulouse site to Sandoz aligns with Evotec's strategy of focusing on scalable technology in its biologics segment.
More info
Endeavour Silver Corp. logo
EX
Endeavour Silver Corp.
EXK
Q2 2025
Reported:

Endeavour Silver reported substantial revenue growth in Q2 2025, bolstered by higher precious metal prices and the integration of the new Kolpa mine, but faced ongoing operational challenges as it approaches commercial production at Terronera.

Key takeaways
  • Production reached 2.5 million silver equivalent ounces, a 13% increase year-over-year, driven by the new Kolpa mine's contribution.
  • Revenue surged by 46% to $85 million, benefiting from improved precious metal prices and production levels.
  • The company incurred a net loss of $20 million due to commissioning losses at Terronera and increased general and administrative costs related to the Kolpa acquisition.
  • Cash costs were maintained below guidance at $15.35 per ounce for payable silver, with all-in sustaining costs recorded at $25 per ounce.
  • Endeavour is on track for a future annual production profile of 20 million silver equivalent ounces, supported by ongoing ramp-up efforts at Terronera and improvements at Kolpa.
More info
Global-E Online Ltd. Ordinary Shares logo
GL
Global-E Online Ltd. Ordinary Shares
GLBE
Q2 2025
Reported:

Global-E reported robust Q2 2025 results, exceeding revenue and GMV guidance, and achieving GAAP profitability for the quarter, underscoring the resilience of its business model amidst market uncertainties.

Key takeaways
  • Q2 GMV reached $1.45 billion, representing a 34% year-over-year increase, with revenue of almost $215 million, up 28%.
  • Achieved a net profit of $10.5 million, marking a significant turnaround from a $22.4 million loss in the same period last year, and is positioned for GAAP profitability moving forward.
  • Adjusted EBITDA rose to $38.5 million, with a margin of 17.9%, reflecting strong operational efficiency.
  • Extended partnership with DHL for an additional three years, enhancing service capabilities for merchants and customers.
  • Remain optimistic about growth prospects despite anticipated regulatory changes, supported by strategic solutions that mitigate tariff impacts.
More info
Hudbay Minerals Inc. logo
HB
Hudbay Minerals Inc.
HBM
Q2 2025
Reported:

Hudbay Minerals delivered robust Q2 2025 results with significant free cash flow generation and a strengthened balance sheet, underscored by a strategic joint venture agreement with Mitsubishi Corporation.

Key takeaways
  • Achieved adjusted EBITDA of $245 million, resulting in a record trailing 12-month adjusted EBITDA of $996 million.
  • Consolidated copper production at 30,000 tonnes and gold production at 56,000 ounces, impacted by wildfires yet supported by resilient operations.
  • Industry-leading cost performance with cash costs at negative $0.02 per pound and sustaining cash costs at $1.65 per pound, well below full year guidance.
  • Reaffirmed full-year production guidance while lowering cost guidance range from $0.80-$1.00 to $0.65-$0.85 per pound.
  • Formed a minority joint venture with Mitsubishi Corporation for the Copper World project, significantly reducing funding requirements and enhancing project valuation.
More info
Hyliion Holdings Corp. logo
HY
Hyliion Holdings Corp.
HYLN
Q2 2025
Reported:

Hyliion Holdings demonstrated significant progress in Q2 2025, overcoming prior manufacturing challenges and resuming deliveries of its KARNO Power Module, bolstered by new favorable legislation encouraging customer adoption.

Key takeaways
  • The passage of the One Big Beautiful Bill Act introduces a 30% investment tax credit for customers adopting Hyliion’s fuel-agnostic technologies, enhancing cost dynamics for potential users.
  • Successful in-house transition of Linear Electric Motor (LEM) production ensures quality and reduces dependency on external suppliers, enhancing production reliability.
  • Delivery of two KARNO Power Modules is imminent, with a total of 10 expected to be delivered to Early Adopters in 2025, despite a shift in full commercialization to 2026.
  • The U.S. Navy continues to test KARNO units, showing robust performance and reliability, with ongoing development supported by a Phase II small business innovation contract worth up to $1.5 million.
  • Continued improvements in the design of the KARNO Power Module aim to increase efficiency, leveraging technical milestones achieved in component production and testing.
More info
i-80 Gold Corp. logo
IA
i-80 Gold Corp.
IAUX
Q2 2025
Reported:

i-80 Gold's Q2 2025 results demonstrate significant progress in its recapitalization efforts and operational advancements aimed at achieving a targeted annual production exceeding 600,000 ounces of gold by the early 2030s.

Key takeaways
  • Completed a pivotal equity raise, enhancing liquidity and supporting the advancement of technical studies and development plans.
  • Increased gold production forecast to rise from less than 50,000 ounces annually to 150,000-200,000 ounces by 2028, driven by high-grade underground projects.
  • High-grade mineral resource base estimated at 6.5 million ounces measured and indicated, with considerable growth upside identified through ongoing drill programs.
  • New COO Paul Chawrun is optimizing operations and accelerating development timelines, leveraging a strong team with extensive Nevada mining experience.
  • Expecting to achieve 30,000 to 40,000 ounces of gold extraction in 2025, consistent with guidance, while dewatering and permitting activities proceed effectively.
More info
IceCure Medical Ltd logo
IC
IceCure Medical Ltd
ICCM
Q2 2025
Reported:

IceCure Medical's first half of 2025 demonstrated strategic regulatory progress for its ProSense device despite a revenue decline attributed to external shipment delays, while strengthening its financial position through a successful rights offering.

Key takeaways
  • Revenue fell to $1.25 million, down from $1.75 million due to shipment delays linked to the Israel-Iran conflict.
  • Gross profit decreased to $349,000, resulting in a gross margin contraction to 28% from 46% year-over-year.
  • The company closed a $10 million rights offering, significantly oversubscribed, providing a robust cash runway for anticipated FDA marketing authorization.
  • Positive adoption trends in Europe were noted, driven by clinical evidence and a string of high-impact presentations at medical conferences.
  • Anticipation of FDA approval for ProSense remains optimistic, with plans for a post-market study already submitted.
More info
Inovio Pharmaceuticals, Inc. logo
IN
Inovio Pharmaceuticals, Inc.
INO
Q2 2025
Reported:

Inovio Pharmaceuticals continues to make significant progress toward FDA approval of INO-3107, forecasting a rolling submission for its Biologics License Application (BLA) within the year, supported by compelling efficacy data.

Key takeaways
  • Successful completion of design verification for the CELLECTRA 5PSP device enables next steps in regulatory milestones for INO-3107.
  • The company plans to request a priority review of the BLA, potentially leading to a mid-2026 PDUFA date.
  • Recent data highlight a sustained reduction in surgery rates for RRP patients treated with INO-3107, marking a significant clinical benefit.
  • The FDA inspection of Inovio as the clinical sponsor has been completed successfully, crucial for ongoing regulatory assessments.
  • Inovio is actively pursuing partnerships to advance its next-generation DNA medicine platforms, including dMAb and DPROT technologies.
More info
Innoviz Technologies Ltd. logo
IN
Innoviz Technologies Ltd.
INVZ
Q2 2025
Reported:

Innoviz Technologies reported Q2 2025 revenues of $9.7 million, surpassing total 2024 revenue, and remains on track to achieve full-year targets of $50 million to $60 million as strategic partnerships expand.

Key takeaways
  • Revenues increased significantly, totaling $27.1 million in the first half of 2025, driven by LiDAR unit sales and new engineering contracts.
  • Cash burn was limited to $7.3 million, consistent with guidance, reflecting improved operational efficiency.
  • Innoviz secured a key development agreement with a top 5 automotive OEM for their Level 3 vehicle program, expected to begin production in 2027.
  • The launch of InnovizSMART for industrial applications has seen immediate collaborations with multiple companies, showcasing the versatility of their LiDAR technology.
  • Increased guidance for non-recurring engineering (NRE) bookings to $30 million to $60 million in 2025, underlining strong demand across existing and new customers.
More info
Inspirato Incorporated Class A Common Stock logo
IS
Inspirato Incorporated Class A Common Stock
ISPO
Q2 2025
Reported:

Inspirato reported a strong Q2 2025 with significant improvements in adjusted EBITDA and a strategic combination with Buyerlink set to enhance growth and operational efficiencies moving forward.

Key takeaways
  • Achieved 96% improvement in adjusted EBITDA year-over-year, totaling $8.8 million.
  • Announced a definitive agreement to combine with Buyerlink, expected to close in Q3, creating a combined revenue of over $350 million.
  • Anticipated financial accretion from the Buyerlink integration, projecting $30 million in adjusted EBITDA on a pro forma basis by 2025.
  • Focused on enhancing operational efficiency, brand elevation, member experience, and digital platform development.
  • Relaunching the Inspirato magazine in Q3 to strengthen brand presence and member engagement.
More info
Kamada Ltd. logo
KM
Kamada Ltd.
KMDA
Q2 2025
Reported:

Kamada Limited reported strong second-quarter results, with total revenues increasing by 5% year-over-year, driven by a diverse product portfolio and effective cost management. The company raised its adjusted EBITDA guidance, reflecting robust growth prospects.

Key takeaways
  • Q2 2025 revenue reached $44.8 million, while first-half revenue totaled $88.8 million, marking an 11% year-over-year increase.
  • Adjusted EBITDA rose 20% year-over-year to $10.9 million in Q2, representing a 25% margin.
  • The company is expanding its biosimilar pipeline and anticipates notable revenue contributions from new products in the next 5 years.
  • FDA approval of a new plasma collection center in Houston boosts capacity, projected to generate $8-10 million annually at full utilization.
  • Kamada is actively pursuing business development and M&A opportunities to enhance its product portfolio and drive future growth.
More info
LogicMark Inc. Common Stock logo
LG
LogicMark Inc. Common Stock
LGMK
Q2 2025
Reported:

LogicMark delivered a robust 22% year-over-year revenue growth in Q2 2025, bolstered by strong sales of its innovative personal safety devices and improved product margins.

Key takeaways
  • Revenue reached $2.9 million, reflecting a 10% sequential increase from Q1 2025.
  • Gross profit increased by 24% year-over-year, with margins rising to 67.5% due to a favorable product mix.
  • Continued investment in product innovation and strategic sales leadership positions LogicMark for accelerated growth in a burgeoning care economy.
  • Strong market response to new products, particularly the upgraded Guardian Alert 911 Plus and Freedom Alert Mini.
  • Transition to the OTC market completed, strengthening business execution focus with no long-term debt and a favorable cash position.
More info
Loar Holdings Inc. logo
LO
Loar Holdings Inc.
LOAR
Q2 2025
Reported:

Loar Holdings, Inc. reported outstanding Q2 2025 results, surpassing all performance metrics with record sales and adjusted EBITDA, demonstrating robust growth across its aerospace-focused portfolio.

Key takeaways
  • Achieved a compound annual growth rate of 37% in sales and 45% in adjusted EBITDA since 2012.
  • Recorded an impressive cash flow conversion percentage of 148% year-to-date, with ongoing expectations to exceed 125% for the full year.
  • A strong pipeline for new product introductions is projected to drive $500 million in sales over the next five years, underpinning future organic growth.
  • Continuous improvement initiatives are expected to enhance productivity and margin growth, despite occasional temporary headwinds.
  • Solidified market position across diverse aerospace sectors, contributing to substantial long-term shareholder value.
More info
Spectral AI Inc. Class A Common Stock logo
MD
Spectral AI Inc. Class A Common Stock
MDAI
Q2 2025
Reported:

Spectral AI Inc. reported a net loss of $7.9 million for Q2 2025, driven by decreased research revenue and increased warrant liabilities, yet maintained a robust cash position to support future initiatives.

Key takeaways
  • Completed a $15 million debt financing agreement and raised $2.7 million in equity, ending the quarter with over $10 million in cash.
  • Achieved a significant milestone with the FDA submission for the DeepView System in June 2025, anticipated to strengthen commercial efforts.
  • Research and development revenue fell to $5.1 million, down from $7.5 million year-over-year, reflecting reduced reimbursements under the BARDA contract.
  • General and administrative expenses decreased to $4.4 million, from $5.8 million, highlighting ongoing operational efficiencies.
  • The net loss for the first half of 2025 improved to $5.1 million compared to $6.1 million in the same period last year, indicating deeper cost management efforts.
More info
Mastech Digital, Inc. logo
MH
Mastech Digital, Inc.
MHH
Q2 2025
Reported:

Mastech Digital reported a stable second quarter in 2025, showcasing year-over-year revenue growth in its IT Staffing and Data Analytics segments despite a slight decline in consolidated revenue.

Key takeaways
  • Consolidated revenue decreased by 0.9% year-over-year to $49.1 million, with IT Staffing Services slightly down by 0.4%.
  • Non-GAAP net income for Q2 2025 was $1.8 million, a decrease from $2.2 million in Q2 2024, but an improvement from Q1 2025.
  • Highest gross margin to date achieved in Q2, attributed to a focus on revenue quality and high-value services in Financial Services.
  • Order bookings in Data and Analytics segment fell to $5.8 million, down from $9.2 million in the previous year, due to slower capital investment decisions.
  • Solid liquidity position with $27.9 million in cash and no bank debt as of June 30, 2025, positioning the company well for future opportunities.
More info
Mineralys Therapeutics Inc. Common Stock logo
ML
Mineralys Therapeutics Inc. Common Stock
MLYS
Q2 2025
Reported:

Mineralys Therapeutics reported strong clinical trial results for lorundrostat, positioning it as a promising treatment for uncontrolled hypertension and related conditions, with significant interest from healthcare providers for future prescriptions.

Key takeaways
  • Pivotal trial data from the Launch-HTN and Advance-HTN studies demonstrated significant reductions in systolic blood pressure, published in major medical journals.
  • A survey indicated that 95% of surveyed cardiologists and primary care physicians are likely to prescribe lorundrostat for patients with resistant hypertension if approved.
  • The company is actively preparing for a pre-NDA meeting with the FDA in Q4 2025, signaling readiness for regulatory submission.
  • Lorundrostat shows potential benefits in patients with comorbidities such as chronic kidney disease and obstructive sleep apnea, broadening its market application.
  • Ongoing pre-commercial efforts include enhancing market access and payer value assessments to support lorundrostat's launch.
More info
M-tron Industries, Inc. logo
MP
M-tron Industries, Inc.
MPTI
Q2 2025
Reported:

M-tron recorded solid Q2 2025 results with revenue growth driven by strong defense orders, although gross margins contracted due to tariff impacts and changes in product mix.

Key takeaways
  • Q2 revenues rose 12.5% to $13.28 million, bolstered by defense-related product shipments.
  • Gross margins decreased to 43.6%, down from 47% year-over-year, largely attributed to federal tariffs and product mix.
  • Net income fell to $1.6 million, or $0.53 per diluted share, from $1.7 million, reflecting margin compression and increased operational expenses.
  • Backlog surged 35% year-over-year to $61.2 million, driven by strong demand in defense and avionics.
  • M-tron is actively investing in R&D to support long-term growth amidst favorable market conditions.
More info
Mersana Therapeutics, Inc. logo
MR
Mersana Therapeutics, Inc.
MRSN
Q2 2025
Reported:

Mersana Therapeutics delivered strong second quarter results, marked by promising clinical data for its lead candidate, Emi-Le, particularly in triple-negative breast cancer (TNBC) and adenoid cystic carcinoma, driving ongoing dose expansion efforts.

Key takeaways
  • Emi-Le demonstrated a 31% objective response rate in B7-H4 high tumor expression patients during the recent ASCO and ESMO presentations.
  • The drug showed a heightened response rate of 56% in a poor-prognosis subgroup with adenoid cystic carcinoma, reinforcing its potential across various tumor types.
  • Enrollment for the Emi-Le Phase I expansion is proceeding well, with over 45 patients already enrolled, and initial data expected in the second half of 2025.
  • Mersana anticipates significant market potential for Emi-Le, particularly among post-topoisomerase 1 patients, as evolving treatment standards create substantial unmet needs.
  • The company achieved a $15 million milestone with partner GSK related to its HER2-targeting Immunosynthen ADC, XMT-2056, currently in Phase I trials.
More info
Madison Square Garden Entertainment Corp. logo
MS
Madison Square Garden Entertainment Corp.
MSGE
Q4 2025
Reported:

Madison Square Garden Entertainment Corp. reported a solid fiscal 2025, achieving revenues of $942.7 million and a 5% increase in adjusted operating income, despite a challenging fourth quarter that experienced a 17% revenue decline.

Key takeaways
  • Full-year revenues reached $942.7 million with adjusted operating income of $222.5 million.
  • Hosted nearly 6 million guests at over 975 live events, with strong attendance at special events and family shows.
  • Landmark revenue achievement of over $170 million from the Christmas Spectacular, selling 1.1 million tickets across 200 performances.
  • Increased share revenue from the Knicks and Rangers, indicating strong growth potential in fiscal 2026 despite fewer home games.
  • Strategic focus on expanding premium hospitality offerings, with renovations driving incremental revenue increases.
More info
OrganiGram Holdings Inc. logo
OG
OrganiGram Holdings Inc.
OGI
Q3 2025
Reported:

Organigram reported a record-breaking Q3 fiscal 2025, showcasing strong performance with continued leadership in Canada's cannabis market and significant international expansion efforts.

Key takeaways
  • Achieved gross and net revenue records, maintaining a 11.6% market share as the top licensed producer in Canada.
  • Gained momentum post-ERP integration disruption, raising overall market share to 12% by the end of July.
  • Strong performance in the edibles category, reaching an 18.2% market share and successful product launches like SHRED Mac 10 party packs.
  • Increased presence in the cannabis beverage market with a 6.2% share, supported by favorable regulatory conditions in various provinces.
  • Continued focus on innovative product development and improved inventory management to enhance market share across categories.
More info
Peyto Exploration & Development Corp. logo
PE
Peyto Exploration & Development Corp.
PEY.TO
Q2 2025
Reported:

Peyto's Q2 2025 performance demonstrated robust growth with a 24% increase in funds from operations year-over-year, as the company navigated short-term market challenges while maintaining low cash costs.

Key takeaways
  • Production rose to nearly 132,000 BOEs/day, an 8% increase compared to Q2 2024.
  • Funds from operations reached $191 million ($0.95/share), bolstered by effective hedging strategies that added $53 million in gains.
  • Cash costs decreased 13% year-over-year to $1.31 per Mcfe, reinforcing Peyto’s leading position in cost efficiency in the sector.
  • Continued success in drilling operations, including a 37% reduction in drilling and completion costs per meter, should enhance future project economics.
  • The company maintains an unchanged 2025 capital expenditure plan of $450 million to $500 million to support sustained production growth amid strategic market positioning.
More info
Performance Food Group Company logo
PF
Performance Food Group Company
PFGC
Q4 2025
Reported:

PFG delivered strong fiscal Q4 2025 results with over $63 billion in revenue, showcasing effective execution of strategy and market share gains despite a challenging foodservice environment.

Key takeaways
  • Organic independent case growth reached 4.6% for the full year, with Q4 growth accelerating to 5.9%.
  • The Convenience segment achieved double-digit profit growth and positive case growth in all four quarters.
  • Strategic focus on high-performing chain accounts resulted in 2.2% case growth for the year and 4.5% in Q4.
  • PFG’s workforce expansion in Foodservice culminated in an 8.8% increase in sales representatives year-over-year, enhancing growth potential.
  • The company remains committed to disciplined M&A and restoring its balance sheet within target ranges.
More info
BiomX Inc. logo
PH
BiomX Inc.
PHGE
Q2 2025
Reported:

BiomX delivered noteworthy advancements in its clinical pipeline during Q2 2025, highlighted by the successful initiation of its Phase IIb trial for BX004 and positive data for BX211, positioning the company well for future growth.

Key takeaways
  • Initiated patient dosing in Phase IIb trial for BX004, targeting cystic fibrosis, with top-line results expected in Q1 2026.
  • Published significant Phase Ib/IIa results for BX004, demonstrating a 500-fold improvement in bacterial reduction without resistance emergence.
  • BX211 received strong endorsements from key opinion leaders following positive Phase II results, emphasizing its potential in treating diabetic foot osteomyelitis.
  • Continued discussions are underway with the U.S. Defense Health Agency regarding BX211's registrational study and FDA feedback expected in H2 2025.
More info
Sky Harbour Group Corporation logo
SK
Sky Harbour Group Corporation
SKYH
Q2 2025
Reported:

Sky Harbour reported a robust second quarter with a significant 82% year-over-year revenue increase, driven by new campus openings and operational improvements, while cash flow usage saw substantial reductions.

Key takeaways
  • Consolidated revenues reached $6.6 million, up 82% YoY, reflecting growth from existing campuses and the acquisition of Camarillo.
  • Operating cash flow improved dramatically to under $1 million used in Q2, down from $5 million in Q1, enhancing expectations for breakeven by year-end.
  • The potential annualized revenue from newly opened campuses is projected at $14 million, underscoring strong growth momentum going into Q3 and Q4.
  • Sky Harbour's revenue capture potential is anticipated to approach $200 million by year-end, bolstered by an effective leasing strategy.
  • Strategic leasing efforts have commenced, focusing on pre-leasing at yet-to-be-constructed campuses.
More info
Similarweb Ltd. logo
SM
Similarweb Ltd.
SMWB
Q2 2025
Reported:

Similarweb reported strong Q2 2025 results with a 17% revenue growth to $71 million and returned to operating profit, underpinned by robust customer growth and an expanding portfolio in generative AI solutions.

Key takeaways
  • Revenue reached $71 million, surpassing expectations, driven by an 18% increase in the customer base to nearly 6,000 ARR customers.
  • Positive free cash flow for the seventh consecutive quarter, coupled with a return to profitability, highlighting operational efficiency.
  • Guidance for 2025 revenue maintained at $285-$288 million, with an increase in profit guidance reflecting confidence in business momentum and multiyear contracts.
  • Strong customer engagement with generative AI solutions, contributing approximately 8% to total revenue and fostering new high-impact opportunities.
  • Net revenue retention (NRR) for overall customers improved to 100%, with a notable increase in multiyear contracts indicating revenue durability.
More info
Tecogen Inc. logo
TG
Tecogen Inc.
TGEN
Q2 2025
Reported:

Tecogen's Q2 2025 performance reflects continued progress in its data center strategy, offset by reduced gross profit margins due to initial production challenges with its new hybrid chiller.

Key takeaways
  • Lower gross profit margins stemmed from initial production and labor costs associated with the hybrid chiller and increased service costs in New Jersey and Manhattan.
  • Significant momentum in the data center sector, with a signed letter of intent for a major 100+ MW project and potential for further expansion based on customer satisfaction.
  • New operational strategies being implemented to enhance labor efficiency and reduce costs, targeting improved service margin above 50% within the next 9 to 12 months.
  • Tecogen's chillers present a unique advantage for cooling power-hungry AI chips, aligning with the increasing demand for efficient data center solutions.
  • Management remains focused on scaling production and addressing supply chain efficiencies to meet growing market demand and maximize shareholder value.
More info
TUI AG logo
TU
TUI AG
TUI1.DE
Q3 2025
Reported:

TUI Group reported record third-quarter results, with revenue rising 8% and a significant EBIT increase of EUR 115 million, prompting an upward revision of the full-year EBIT guidance to 9% to 11%.

Key takeaways
  • EBIT for Q3 reached EUR 321 million, the highest ever for this quarter, driven by strong performance in Hotels & Cruise.
  • Summer bookings are down 2%, but average selling prices increased by 3%, reflecting resilience in a competitive market.
  • Dynamic package share growth is a key focus, with a new connection to airline and hotel content enhancing future growth potential.
  • Strong demand for differentiated products contributed to record occupancy rates and higher pricing power, particularly in the Holiday Experiences segment.
  • Continued international expansion of Musement services into new markets is poised to further capitalize on revenue opportunities.
More info
uCloudlink Group Inc. logo
UC
uCloudlink Group Inc.
UCL
Q2 2025
Reported:

uCloudlink reported steady growth in Q2 2025 with a total revenue of $19.4 million and net income of $0.7 million, driven by robust performance across its GlocalMe product lines.

Key takeaways
  • Total revenue increased to $19.4 million, while net income remained positive at $0.7 million, showcasing continued profitability.
  • The GlocalMe ecosystem demonstrated significant user engagement, with average monthly active terminals growing 105.2% for GlocalMe Life, 120.1% for GlocalMe SIM, and an impressive 791% for GlocalMe IoT.
  • The upcoming commercial launch of the GlocalMe Life platform includes partnerships with over 20 potential strategic partners, enhancing market penetration and service offerings.
  • Continued investment in R&D and strategic partnerships positions uCloudlink to lead in the growing global roaming market and capitalize on high-demand sectors such as IoT connectivity.
More info
VerifyMe, Inc. logo
VR
VerifyMe, Inc.
VRME
Q2 2025
Reported:

VerifyMe reported Q2 2025 revenues of $4.5 million, a 16.7% decline year-over-year, primarily due to loss of major customers; however, the company achieved a positive adjusted EBITDA of $0.3 million and reduced operating expenses by 27%.

Key takeaways
  • Revenue decreased by $0.9 million from Q2 2024, driven by discontinued contracts in premium services.
  • Gross profit margin declined to 35%, but improvements in proactive services provided some offset.
  • Operating expenses were reduced to $1.9 million, benefiting from cost-cutting measures and divestitures.
  • Cash balance increased to $6.1 million, with $0.7 million generated from operations, indicating positive cash flow moving forward.
  • A new treasury strategy aims to enhance interest income from cash reserves, targeting annualized returns exceeding 8%.
More info
Vestas Wind Systems A/S logo
VW
Vestas Wind Systems A/S
VWDRY
Q2 2025
Reported:

Vestas achieved a 14% year-on-year revenue growth to EUR 3.7 billion in Q2, but faced a significant decline in order intake, notably in the U.S., amid policy uncertainties.

Key takeaways
  • EBIT margin decreased to 1.5% due to increased offshore ramp-up costs, despite improved onshore project performance.
  • Order intake fell 44% year-on-year to 2 gigawatts, primarily impacted by customer hesitance regarding U.S. policy clarity.
  • Return on capital employed improved to 11.5%, marking the highest ROCE since 2020, driven by enhanced profitability over the last 12 months.
  • The service order backlog increased to EUR 36 billion, with gigawatts under service rising to 159, reflecting ongoing recovery efforts.
  • Despite challenges, the company maintains its 2025 outlook guidance, with early Q3 signs of order momentum returning.
More info

📊 Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector